Shuwen Liu
Dr. Shuwen Liu is a professor of pharmacology, Southern Medical University, China. Now he is the vice president of Southern Medical University, and the dean of the Graduate School. Dr. Liu is also the director of Guangdong Provincial Key Laboratory of Drug Screening. He got his doctoral degree in pharmacology in 2002 from the First Military Medical University, China. After that, he worked as post-doctor and then assistant member in New York Blood Center from 2002 to 2005. Dr. Liu is the chairman of Division of Anti-inflammatory and Immunopharmacology of Chinese Pharmacological Society (CPS), the chair-elect of Guangdong Pharmaceutical Society, and the vice chairman of Guangdong High Performance Computing Society.
Dr. Liu's research focused on anti-viral drug development and immunopharmacology, especially to find new agents treating virus resistance and latency. He was awarded more than 30 research grants. From 2002, Dr. Liu has already published more than 200 SCI papers in academic journals like Lancet, Chem Sci, Brit J Pharmacol, AIDS, J Biol Chem, etc., which were cited more than 6,400 times with an h-index of 36. Moreover, Dr. Liu got 32 Chinese patents and 1 United States patent, as well as 30 Chinese and PCT patent applications. He also served as the member of editorial board of journals like BBA-Biomembrances, Acta Pharmacologica Sinica, etc.
Dr. Liu's research focused on anti-viral drug development and immunopharmacology, especially to find new agents treating virus resistance and latency. He was awarded more than 30 research grants. From 2002, Dr. Liu has already published more than 200 SCI papers in academic journals like Lancet, Chem Sci, Brit J Pharmacol, AIDS, J Biol Chem, etc., which were cited more than 6,400 times with an h-index of 36. Moreover, Dr. Liu got 32 Chinese patents and 1 United States patent, as well as 30 Chinese and PCT patent applications. He also served as the member of editorial board of journals like BBA-Biomembrances, Acta Pharmacologica Sinica, etc.
Selected Publication:
1. Liu SW#, Xiao GF#, Chen YB, He YX, Niu JK, Escalante CR, Xiong HB, Farmar J, Debnath AK, Tien P, Jiang SB*. Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, 2004; 363(9413): 938-947
2. Liu SW, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion Inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. Journal of Biological Chemistry. 2005; 260(12): 11259-11273
3. Pan XY, Zhao W, Wang CY, Lin J, Zeng XY, Ren XX, Wang K, Xun TR, Shai Y*, Liu SW*. Heat shock protein 90 facilitates latent HIV reactivation through maintaining the function of positive transcriptional elongation factor b (p-TEFb) under proteasome inhibition. Journal of Biological Chemistry. 2016; 291(50): 26177-26187.
4. Zeng XY, Pan XY, Xu XF, Lin J, Que FC, Tian YX, Li L, Liu SW*. Resveratrol reactivates latentHIV through increasing histone acetylation and activating heat shock factor 1. Journal of Agricultural and Food Chemistry. 2017; 65(22): 4384-4394.
5. Li L, Qiu JY, Lu L, An SL, Qiao P, Jiang SB, Liu SW*. 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. Journal of Antimicrobial Chemotherapy. 2013; 68(3): 573-576
6. Zhu ZB, Li RM, Xiao GK, Chen ZP, Yang J, Zhu QH, Liu SW*. Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion. European Journal of Medicinal Chemistry. 2012, 57: 211-6.
7. Tan SY*#, Li JQ#, Cheng HY, Li ZF, Lan Y, Zhang TT, Yang ZC, Li WJ, Qi T, Qiu YR, Chen ZP, Li L, Liu SW*.. The anti-parasitic drug suramin potently inhibits formation of seminal amyloid fibrils and their interaction with HIV-1. Journal of Biological Chemistry. 2019; 294(37): 13740-13754.
8. Lin J#, Zhang XX#, Lu WZ, Xu XF, Pan XY, Liang TZ, Duan SQ, Chen Y, Li L, Liu SW*. PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1. Biochemical Pharmacology. 2018; 156: 511-523.
9. Cao Y, Chen SJ, Liang YM, Wu T, Pang JX, Liu SW*, Zhou PZ*. Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by beta-blocker carvedilol. British Journal of Pharmacology. 2018; 175(20): 3963-3975.
10. Liu T, Liu MM, Chen FM, Chen FZ, Tian YX, Huang Q, Liu SW*, Yang J*. A small-molecule compound has anti-influenza A virus activity by acting as a ‘‘PB2 inhibitor”. Molecular Pharmaceutics. 2018; 15(9): 4110-4120.
11. Shi LL, Yu L, Zhong DS, Gu CP, Lv LY, Zeng XY, Yao XG, Li L, Liu SW*. TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules. AIDS. 2018; 32(9): 1107-1114.
12. Shen XT#, Zhu ZB#, Ding Y, Wu WJ, Yang J, Liu SW*. An oligothiophene compound neutralized influenza A viruses by interfering with hemagglutinin. Biochimica et Biophysica Acta-Biomembranes, 2018; 1860(3): 784-791.
13. Xun TR, Li WJ, Chen JQ, Yu F, Xu W, Wang Q,Yu RZ ,Li XJ, Zhou XF, Lu L ,Jiang SB, Li L, Tan SY*, Liu SW*. ADS-J1 Inhibits Semen-derived Amyloid Fibril Formation and Blocks Fibril-mediated Enhancement of HIV-1 Infection. Antimicrobial Agents and Chemotherapy, 2015; 59(9): 5123-5134.
14. Tan SY, Duan H, Xun TR, Ci W, Qiu JY, Yu F, Zhao XY, Wu LX, Li L, Lu L, Jiang SB, Liu SW*. HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. Laboratory Investigation. 2014, 94(7): 777-787.
15. Tan SY, Li L, Lu L, Pan CG, Lu H, Oksov Y, Tang XJ, Jiang SB*, Liu SW*. Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection. FEBS Letters. 2014, 588: 1515-1522.
No items yet!
-
Supervisor
24-Dec-01
